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Objective: Lung injury after cardiopulmonary bypass includes pulmonary hyperten-
sion and lung edema. Both complications are related to endothelial pulmonary
vascular dysfunction, leukocyte sequestration, and increased capillary permeability.
This study was done in an attempt to better define the endothelial dysfunction and
the cause of edema.
Methods: Twenty-five neonatal piglets were subjected to total cardiopulmonary
bypass for 90 minutes without crossclamping of the aorta. After weaning from
cardiopulmonary bypass, they were allowed to survive 2 hours, at which time they
were killed. Preoperative and postoperative hemodynamic studies, lung (n  16)
and muscular (n 5) vascular endothelial growth factor contents, and exhaled nitric
oxide (n  8) were recorded. Immediately after the animals were killed, pulmonary
arterial rings were obtained from 12 piglets and mounted in organ chamber for
assessment of endothelial function with receptor-dependent (acetylcholine) or non–
receptor-dependent (calcium ionophore A23187) studies and compared with control
pulmonary arterial rings. The left lungs of 13 piglets were mounted in isolated
perfused lung chambers for filtration coefficient assessment and comparison with
control preparations.
Results: After cardiopulmonary bypass, pulmonary vascular resistance increased
from 953.7  302.6 dyne  s  cm5 to 1973.6  925.4 dyne  s  cm5 (P 
.03). This was associated with an increase in lung vascular endothelial growth factor
content from 91.07  5.314 pg/100 mg tissue to 151.6  11.4 pg/100 mg tissue
(P .0001), an increase in muscle vascular endothelial growth factor from 76.02
11.53 pg/100 mg tissue to 81.58  7.7 pg/100 mg tissue (P not significant), and a
decrease in exhaled nitric oxide from 6 1.7 ppb to 3.12 1.4 ppb (P .003). The
filtration coefficient was statistically significantly higher after cardiopulmonary
bypass than in control preparations (0.259  0.02 vs 0.525  0.07, P  .0001).
Variations in lung vascular endothelial growth factor accumulation were statistically
significantly higher than in muscular vascular endothelial growth factor accumula-
tion (60.5  9.1 vs 5.5  5.9, P  .0008). In addition, a statistically significant
correlation was found between postbypass lung vascular endothelial growth factor
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and lung filtration coefficient (P  .0058), as well as between change in lung
vascular endothelial growth factor and change in lung filtration coefficient (P 
.03). Pulmonary vascular endothelial receptor-dependent (acetylcholine) function
was statistically significantly blunted after bypass relative to control values (15.44%
 4.8% vs 55.5%  5.96% of maximal relaxation, P  .0001), whereas non–
receptor-dependent endothelial function was unaffected by cardiopulmonary bypass
(110.77%  8.9% vs 120.63%  15.46% of maximal relaxation, P not significant).
Conclusions: These findings suggest that lung ischemia that occurs during cardio-
pulmonary bypass affects the signal transduction from membrane receptors to
intracellular calcium mobilization and nitric oxide synthase activation. Lung edema
after bypass is probably due in part to lung accumulation of vascular endothelial
growth factor, a finding that was not found in systemic muscular nonischemic
territories.
Cardiac surgery for repair of acquired orcongenital heart defects mandates in thevast majority of cases the use of cardiopul-monary bypass (CPB). In the early days ofCPB, pulmonary complications caused asignificant percentage of the attendant mor-
bidity and mortality.1 In the last decades, during which time
CPB has become commonplace, improvements in technol-
ogy and better understanding of the pathophysiology of lung
injury after these procedures have reduced the incidence of
pulmonary complications; they still remain a problem, how-
ever, particularly in neonates and small children. Acute
pulmonary hypertension with decreased gas exchange and
low cardiac output are not uncommon, and microscopic
alterations of the lung parenchyma have been demonstrat-
ed.2 In addition, post-CPB ventilation may be more difficult
because of subclinical lung edema. Post-CPB lung dysfunc-
tion is probably multifactorial; the inflammatory response to
CPB and the lung ischemia-reperfusion injury during CPB
have been demonstrated to be the main causes for this
dysfunction.3 One of the most common feature after CPB is
an elevation of pulmonary vascular resistance (PVR),3
which has been attributed to the inability of pulmonary
vascular endothelium to produce nitric oxide to maintain a
low tone in the pulmonary arterial tree. The reasons for that
endothelial dysfunction, although probably multifactorial,
remain unknown.
Recently a strong body of publications have shown a
tight relation between nitric oxide production and vascular
endothelial growth factor (VEGF). VEGF is a soluble 46-kd
angiogenic glycoprotein that exerts its biologic function
through high-affinity tyrosine kinase receptors.4 VEGF has
been shown to have several biologic functions. In addition
to its involvement in angiogenesis, it induces an endotheli-
um-dependent vasodilatation that is inhibited by nitric oxide
synthase (NOS) inhibitors.5 Brock and colleagues6 demon-
strated that VEGF increased cytosolic calcium, which pro-
motes calmodulin binding to the endothelial isoform of
NOS and stimulates nitric oxide production.7 More recently,
this effect of VEGF on nitric oxide production has been
associated with upward regulation of endothelial cell NOS
activity.8 In addition, VEGF has been recognized to be
encoded by the very same gene that encodes for vascular
permeability factor, a protein that promotes extravasation of
proteins from tumor-associated blood vessels.9 In addition,
VEGF has been demonstrated to prevent endothelial cell
apoptosis through the phosphatidylinositol 3-kinase/Akt
signal transduction pathway10 and inhibits leukocyte-endo-
thelium interactions.11
Hypoxia and ischemia are major stimulators of VEGF
expression.12 Hypoxia-induced transcription of VEGF mes-
senger RNA is apparently mediated at least in part by the
binding of hypoxia-inducible factor 1 to a hypoxia-induc-
ible factor 1 binding site located in the VEGF promoter.13
Interleukin 1 and interleukin 6 are also strong stimulators
of VEGF production.14
We therefore hypothesize that during CPB, strong stim-
ulation for VEGF lung production or receptors expression
might be present through hypoxia-ischemia mechanisms as
well as through the production of various cytokines. There-
fore an increase in pulmonary vascular lung nitric oxide
production should be observed, which is in contrast with
previous observations, namely decreases in nitric oxide
production15 and endothelial cell apoptosis16,17 and in-
creased leukocyte-endothelium interactions.3 This study
was an attempt to demonstrate that during CPB there is a
stimulus for lung VEGF accumulation but that signal trans-
duction to produce nitric oxide fails. In addition, if VEGF is
produced in excess, capillary permeability should be in-
creased.
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Material and Methods
The experimental protocol was divided into two parts. The first
part was an in vivo hemodynamic study before and after CPB.
Measurements of exhaled nitric oxide and assay of biopsy speci-
mens for VEGF lung and skeletal muscle quantification were
obtained before and after CPB. The second part assessed pulmo-
nary vascular reactivity with particular pharmacologic dissection
of the signal transduction for nitric oxide production by endothelial
cells after CPB versus a control group. Finally, in a last group of
experiments, post-CPB pulmonary capillary permeability was as-
sessed in isolated perfused lungs and compared with that in control
lungs not subjected to CPB.
Twenty-five neonatal piglets (mean age 7 days, mean weight
3.2 kg) were purchased from a local farmer. All animals received
humane care in compliance with the “Principles of Laboratory
Animal Care” formulated by the National Society for Medical
Research and the Guide for the Care and Use of Laboratory
Animals prepared by the Institute of Laboratory Animal Resources,
National Research Council, and published by the National Acad-
emy Press, revised 1996. They were kept without food for 12 hours
before the operation, sedated with intramuscularly injected ket-
amine (10-15 mg/kg), and anesthetized with thiopental (3-5 mg/kg
intravenously). Analgesia was maintained throughout the experi-
mentation with fentanyl (3-5 g/[kg  min]). Subsequently, the
animals were intubated and general anesthesia was maintained
with nitrous oxide (60%) and oxygen (40%) under intermittent
positive-pressure ventilation (MMS 107 ventilator; S.N.E.H., Gon-
esse, France) at 40 breaths/min with a tidal volume of 15 mL/kg.
With the animal in a supine position, the right femoral artery was
isolated. After femoral arterial cannulation, ventilatory rate and
tidal volume were adjusted to establish a normal pH and PCO2, as
determined by arterial blood gas measurement (ABL2; Radiometer
Medical A/S, Brønshøj, Denmark). After midline sternotomy and
pericardiotomy, the ductus was ligated and the great vessels were
controlled. A pulmonary artery catheter (Intracath, Deseret Med-
ical, Inc, Sandy, Utah) was introduced into the main pulmonary
artery through the right ventricular infundibulum, and cardiac
output was recorded with a Doppler probe placed around the
pulmonary artery trunk (model T106 M; Transonic Systems, Inc,
Ithaca, NY). The central venous and left atrial pressures were
monitored after placement of indwelling catheters in the right and
left atria. Pressure recording was performed with the P23 ID
Statham pressure transducer (Statham, Paris, France). After hepa-
rin administration (3 mg/kg), CPB was instituted between the right
atrium with the arterial return directed into the ascending aorta.
The bypass circuit consisted in a cardiotomy reservoir and a
membrane oxygenator (Safe Micro; Polystan A/S, Værløse, Den-
mark), a heat exchanger, and a roller pump. No arterial filter was
used. The circuit was primed (400 mL) with whole blood obtained
from a donor pig the day before surgery. Within the first 5 minutes
of CPB, a vent was introduced through the left ventricular apex.
Mean systemic arterial pressures were maintained to prebypass
values with a mean flow of 500 mL/min. After a steady state was
obtained under CPB, ventilation was stopped and cooling to 33°C
was started. The pulmonary artery trunk was crossclamped to
avoid any antegrade flow to the lungs, and CPB was maintained for
90 minutes without aortic crossclamping. After this period me-
chanical ventilation was reinstituted and the piglets were weaned
from CPB. They were allowed to survive 2 hours and then killed.
The pulmonary arterial vessels were dissected beyond the second-
generation branch and mounted in an organ chamber for vascular
reactivity evaluation.
Physiologic Measurements
Hemodynamic measurements were made before institution of CPB
and 120 minutes after cessation of CPB. Cardiac output was
determined as pulmonary blood flow (Qpa) in liters per minute.
PVR was calculated as follows:
PVR  (PAP  LAP)/Qpa  79.9
where PAP is the mean pulmonary arterial pressure and LAP is the
mean left atrial pressure.
Biopsy specimens were obtained from the lungs (n  16) and
from skeletal muscle (n 5) before and 120 minutes after CPB for
VEGF assessment. They were frozen at 80°C until processing.
Evaluation of Lung Nitric Oxide Production
Exhaled nitric oxide was measured as follow. The expiratory
circuit was disconnected from the ventilator and connected to a
polypropylene bag (150 mL). Nitric oxide was immediately mea-
sured within the bag with a rapid-response chemiluminescent
analyzer (NOX 4000; SERES, Aix en Provence, France). The
analyzer was calibrated before use with serial dilutions of a stan-
dard nitric oxide gas. The lower limit of the sensitivity was 2 ppb.
Measurements of inspired gas in the room were taken as a prelude
to the investigation and suggested a level of 2 ppb nitric oxide. At
each measurement the mean of three samples was recorded. Al-
though this method does not eliminate upper airway nitric oxide
metabolism, prebypass and postbypass values were assumed to
include the same bias.
Lung and Muscular VEGF Assessment
VEGF assessment was performed according to the method de-
scribed by Turnage and coworkers.18 Tissues were pulverized and
homogenized with a Polytron homogenizer (Brinkmann Instru-
ments, Inc, Westbury, BY) in a buffer solution (tris[hydroxymeth-
yl]aminomethane hydrochloride at 0.05 mol/L and ethylenediami-
netetraacetic acid at 0.1 mmol/L, pH 7,40) containing protease
inhibitors (leupeptin at 10 mol/L, pepstatin at 1 mol/L, phenyl-
methylsulfonyl fluoride at 1 mmol/L) and 3-[(3-cholamidopropy-
l)dimethylammonio]-1-propane sulfonate at 20 mmol/L. The ho-
mogenate was sonicated on ice for 15 seconds, frozen (at 70°C)
and thawed two times, and then centrifuged at 40000g for 20
minutes. VEGF concentration in the supernatant was then assessed
with specific antibody for human VEGF165 (Quantikine; R&D
Systems, Minneapolis, Minn). Results are expressed in picograms
per 100 mg tissue.
Isolated Pulmonary Arterial Ring Studies
At the end of each experiment, left and right intrapulmonary
arterial segments were dissected out and placed in warm Krebs-
Henseleit buffer composed of 118.3-mmol/L sodium chloride,
4.7-mmol/L potassium chloride, 2.5-mmol/L calcium chloride,
1.2-mmol/L potassium phosphate, 1.2-mmol/L magnesium sulfate,
25-mmol/L sodium hydrogen carbonate, 0.03-mmol/L ethyl-
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enediaminetetraacetic acid, and 11.1-mmol/L glucose. Isolated
pulmonary arteries were cleaned and cut into rings 3 to 4 mm in
length (1-2 mm outer diameter). From 12 to 16 rings were obtained
from each animal. The rings were then mounted on stainless steel
hooks, suspended in 10-mL tissue baths, and connected to force
displacement transducers (LB-5; Showa-Sokki Corp, Tokyo, Ja-
pan) to record changes in force by the use of chart recorder (LR
4210; Yokogawa Corporation of America, Newman, Ga). The
baths were filled with 10 mL Krebs-Henseleit buffer and aerated at
37°C with a gas mixture of 95% oxygen and 5% carbon dioxide.
Pulmonary arterial rings were initially stretched to produce a
preload of 1g of force and equilibrated for 60 to 90 minutes. A
preload of 1g was proved to be the optimal resting tension by
length-tension analyses performed in pilot studies. This value is
close to the optimal resting tension (1.060g  0.040g) found by
Liu and coworkers19 in piglet neonatal pulmonary arterial rings.
During this period, the Krebs-Henseleit buffer in the tissue baths
was replaced every 10 minutes. After incubation with indometh-
acin (105 mol/L) for 60 minutes, a concentration-response curve
to phenylephrine was obtained. The rings were then washed, and
the developed force was allowed to return to baseline. The rings
were then precontracted with phenylephrine to generate 1g of
developed force. Once a stable contraction was obtained, different
pharmacologic protocols were performed.
● Cumulative doses of acetylcholine (109-104 mol/L) were
added to the bath to assess changes in endothelium-dependent
relaxation.
● Cumulative doses of calcium ionophore (109-105 mol/L)
were added.
● Cumulative doses of acetylcholine with the NOS inhibitor
N-monomethyl-L-arginine (L-NAME (103 mol/L) were
added.
● Cumulative doses of calcium ionophore with L-NAME (10–3
mol/L) were added.
In addition to the change in force, responses were assessed by
determining the concentration that produced 50% of the maximal
response (EC50), extrapolated from a plot of log concentration
versus percentage of maximal response. The contractile response
to phenylephrine were expressed in absolute values (g), and the
maximum relaxations to acetylcholine and calcium ionophore
were expressed as percentages of the phenylephrine-induced pre-
contraction, with 0% indicating no relaxation and 100% indicating
a relaxation equals to that of the precontraction. Post-CPB pulmo-
nary arterial rings were compared with control pulmonary arterial
rings obtained from matched piglets that did not undergo CPB.
Isolated Perfused Lung
The left lung was harvested and suspended by the left main
bronchus to a force-displacement transducer placed in a humidified
chamber to allow monitoring of weight changes. An MMS 107
respirator (S.N.E.H., Gonesse, France) set at 20 breaths/min with
a tidal volume of 200 mL and a positive end-expiratory pressure of
2 cm H2O was used to ventilate the left lung with a humidified
warm gas mixture (20% oxygen, 75% nitrogen, and 5% carbon
dioxide). The lung was perfused with 300 mL of heparinized
autologous blood through a cannula placed in the left pulmonary
artery. A constant flow of 0.03 mL/g body weight was maintained
with a peristaltic pump (Ismatec; Bioblock, Strasbourg, France)
placed in series with the arterial line. Venous blood was collected
by gravity into a reservoir through a cannula in the left atrium and
was recirculated for 60 minutes. To prevent loss of reservoir
volume through retrograde perfusion of the bronchial circulation,
the bronchial arteries were ligated. PAP and pulmonary venous
pressure (PVP) were continuously monitored with pressure trans-
ducers (model P23 ID) placed proximal to the lung, on the arterial
line and on the venous line, respectively. Pressure signals were
amplified (model M52; Telco) and recorded on a polygraph re-
corder (Solar 8000, Marquette, Milwaukee, Wis). Zone 3 condi-
tions (arterial  venous  alveolar pressures) were maintained
throughout all experiments.
Measurements of Pulmonary Hemodynamics and
Microvascular Lung Permeability
Pulmonary capillary pressure (Pc) was estimated with the double-
occlusion method.20 With this method, after simultaneous occlu-
sion of the arterial and venous line, PAP and PVP equilibrate to the
same pressure, which is well correlated with Pc. Pulmonary
arterial resistance (Ra) and venous resistance (Rv) were calculated
as follows:
Ra  (PAP  Pc)/Q
Rv  (Pc  PVP)/Q
where Q is the flow.
The filtration coefficient (Kfc) was used as an index of endo-
thelial permeability to fluid and was measured by the isogravimet-
ric method described by Hakim and Kelly.21 Briefly, after an
isogravimetric period of 30 minutes, PVP was rapidly increased by
20 cm H2O for 20 minutes by raising the outflow end of the venous
reservoir connected to the left atrial cannula. The resultant increase
in lung weight was recorded. The characteristic rapid weight gain
from vascular bed filling was followed by a phase of slower weight
gain reflecting filtration of fluid into the pulmonary interstitium.
The rate of slow weight change (	W/	t) was analyzed with linear
regression of the log10-transformed weight changes per minute.
The initial rate of weight gain was calculated by extrapolating
	W/	t to time 0. Kfc was obtained by dividing 	W/	t at time 0 by
the change in Pc that occurred after the venous outflow pressure
increase, normalizing the result for the baseline wet lung weight,
and expressing it in milliliters per minute per centimeter of water
per 100 g lung tissue. Baseline wet lung weight was estimated by
measuring the weight of the left lung at the beginning of the
experiment and subtracting the weight of the extrapulmonary
tissue measured after reperfusion.
Statistical Analysis
Results are expressed as mean SD. Comparison were performed
with paired and unpaired 2-way analysis of variance. The Spear-
man rank correlation test was performed to assess any correlation
between lung VEGF values and Kfc.
Results
Hemodynamic Values
Two hours after weaning from 90 minutes of CPB, only
PAP and PVR were statistically significantly increased rel-
ative to pre-CPB measures (Table 1).
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Exhaled Nitric Oxide and VEGF Quantification
After CPB there were a statistically significant decrease in
exhaled nitric oxide (6  1.7 ppb before bypass versus
3.12  1.4 ppb after bypass, P  .003), a statistically
significant increase in lung VEGF (from 91.07  5.314
pg/100 mg tissue to 151.6  11.4 pg/100 mg tissue, P 
.0001), and an increase in muscle VEGF (from 76.02 
11.53 pg/100 mg tissue to 81.58  7.7 pg/100 mg tissue, P
not significant). Variation in lung VEGF accumulation was
statistically significantly higher than that in muscular VEGF
accumulation (60.5 9.1 vs 5.5 5.9, P .0008; Table 2).
Pulmonary Vascular Reactivity
In pulmonary vessels, similar maximal contractions to
phenylephrine were observed in all groups of vascular rings.
The EC50 to phenylephrine after CPB was not different from
that in control animals not subjected to CPB.
Maximal relaxation response to acetylcholine was re-
duced after bypass to 30% of control values (P  .0001;
Figure 1). EC50 for acetylcholine was nearly unchanged
before and after CPB, ranging from 8.5 108 to 1.8 107
mol/L. These results indicate that endothelium-dependent
relaxation of pulmonary artery was impaired after CPB.
Addition of L-NAME significantly reduced the relaxation in
control vascular rings, but to a less extent that in post-CPB
pulmonary vessels (from 55.5%  5.96% to 18.5%  4.1%
of relaxation in control pulmonary arterial rings vs when
L-NAME was added and from 15.44%  4.8% to 6.26% 
3.7% in post-CPB rings, P  .04)
In another series of pulmonary arterial rings, after pre-
contraction with phenylephrine, cumulative doses of cal-
cium ionophore were added to the bath. Maximal relaxation
response to calcium ionophore was unchanged from control
values (120.63%  15.46% in control rings vs 110.77% 
8.9% in post-CPB rings, P not significant; Figure 2). EC50
values for calcium ionophore were similar before and after
CPB. Addition of L-NAME in the bath reduced the relax-
ation in both control and post-CPB pulmonary arterial rings
to the same extent (from 120.63%  15.46% to 62.8% 
7.35% in control rings and from 110.77%  8.9% to
43.37%  6.3% in post-CPB rings, P not significant).
Isolated Lung Study
This approach demonstrated statistically significant in-
creases in PVR and in Kfc after CPB versus control (PVR
1.235  0.31 dyne  s  cm5 vs 0.422  0.25 dyne 
s cm5, P .01, Kfc: 0.525 0.07 vs 0.249 0.02, P
.0001; Table 3). In addition, statistically significant corre-
lations were found between postbypass lung VEGF and
lung Kfc (P  .0058) and between change in lung VEGF
and change in lung Kfc (P  .03).
Discussion
This study confirms some previously demonstrated findings
and opens new perspectives on CPB pathophysiology. As
previously demonstrated, CPB is responsible for pulmonary
hypertension through complex mechanisms associated with
ischemia-reperfusion and cytokine production and blunts
the pulmonary vascular endothelial ability to maintain a low
TABLE 2. Assessment of lung VEGF content and exhaled nitric oxide before and after CPB
Animals
assessed Before CPB After CPB
Lung VEGF (pg/100 mg tissue) 16 91.07 5.31 151.6 11.4*
Muscle VEGF (pg/100 mg tissue) 5 76.02 11.53 81.6 7.7
Exhaled nitric oxide (ppb) 8 6 1.7 3.12 1.4†
All values are mean  SD.
*P  .01.
†P  .003.
TABLE 1. Hemodynamic values before and after CPB
Before CPB
(n  12)
60 min after CPB
(n  12)
Systemic pressure (mm Hg, mean  SD) 45 5.04 49.8 11.5
Left atrial pressure (mm Hg, mean  SD) 4.5 1.3 5.4 1.8
Right atrial pressure (mm Hg, mean  SD) 3.4 1.2 3.75 1.5
PAP (mm Hg, mean  SD) 11.42 2.14 16.5 4.23*
PVR (dyne  s  cm5, mean  SD) 982.8 327.6 1829.7 862.9†
Cardiac output (mL/min) 780 733
*P  .01.
†P  .03.
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vascular tone within the pulmonary arterial bed. Although
this information has led to the clinical use of inhaled nitric
oxide, few authors have tried to define the exact sequence of
events that lead to endothelial dysfunction. This work
shows that during CPB there is an accumulation of VEGF
within the lungs and, as previously described elsewhere,15
there is a decrease in exhaled nitric oxide. Although the
method used to assess the quantity of exhaled nitric oxide
was not accurate for true alveolar nitric oxide production, in
both settings the same bias was introduced before and after
CPB, and the variations in nitric oxide production were thus
taken into account. In addition, measurements of lung
VEGF were obtained from tissue homogenate, which in-
cludes epithelial and smooth muscles cells as well as endo-
thelial cells. Although this measurement does not reflect the
true pulmonary endothelial production of VEGF, the vari-
ations of this measure were considered to represent a global
growth factor production or accumulation that could have
vascular effects. These observations are in contrast with the
physiologic experiments, which showed that VEGF produc-
tion is responsible for vasodilatation through an endothelial
and nitric oxide–mediated mechanism. Therefore in the
setting of CPB, accumulation of VEGF in the lungs tissue
and vasculature should be responsible for a pulmonary
arterial tree vasodilatation associated with an increase in
nitric oxide production.
In vitro experiments on arterial rings showed that endo-
thelium-dependent vasodilatation to acetylcholine was
blunted after CPB. Acetylcholine, through membrane mus-
carinic receptors, activates G protein, which subdivides in 
and  subunits. This in turns activates the phospholipase C
and inositol pathway, which eventually mobilizes calcium
from intracellular stores. Increases in intracellular calcium
then activate NOS, leading to nitric oxide production. On
the other side, calcium ionophore is not a receptor-depen-
dent agonist and itself leads to an increase in intracellular
calcium. Therefore in pulmonary arterial rings after total
CPB it appears that the signal transduction from membrane
receptors to increased intracellular calcium is impaired.
This approach was previously used by Evora and associ-
ates22 in coronary arteries rings to demonstrate G protein
dysfunction after myocardial ischemia and reperfusion in
the dog. In addition, Chang and colleagues23 showed that G
protein dysfunction could be attenuated by continuous
warm blood cardioplegia. This finding has, however, to the
Figure 2. Relaxation curves to endothelial non–receptor-depen-
dent agonist calcium ionophore in pulmonary arterial rings after
CPB (filled circles) and in non-CPB control rings (open circles).
TABLE 3. Hemodynamic values and Kfc assessment in iso-
lated perfused lungs after CPB and in non-CPB control
animals
After CPB
(n  13)
No CPB (control,
n  10)
PAP (mm Hg) 29.3 8 16.6 3.9
Capillary pressure (mm Hg) 10.1 4.04 8.7 3.56
Kfc 0.525 0.07 0.249 0.02*
PVR (dyne  s  cm5) 1.235 0.31 0.422 0.25*
All values are mean  SD.
*P  .01.
Figure 1. Relaxation curves to endothelial receptor-dependent
agonist acetylcholine in pulmonary arterial rings after CPB (filled
circles) and in non-CPB control rings (open circles). Asterisk
indicates P  .0001.
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best of our knowledge not been demonstrated in the pulmo-
nary vascular bed after CPB. As a preliminary report, one
may conclude that CPB through lung ischemia-reperfusion
injury is responsible for endothelial G protein dysfunction,
leading to an impairment of signal transduction from the
membrane receptor to the intracellular calcium mobiliza-
tion.
On the other side, VEGF through its membrane tyrosine
kinase receptors activates the phospholipase C and inositol
pathway that mobilizes calcium from intracellular stores
without any activation of G protein.24 Therefore the finding
that after CPB there is a pulmonary accumulation of VEGF
that does not in turn promote endothelial nitric oxide secre-
tion means that post-CPB pulmonary artery endothelial
dysfunction is due to endothelial membrane lesion. In vitro
dissection of these processes to point out the impaired
sequence of signal transduction is still under evaluation.
Indeed, cellular membrane lesions have been documented
after ischemia-reperfusion.25 The following sequence of
events can be therefore proposed. During CPB, the lungs are
subjected to an ischemic process because there is no more
antegrade flow through the main pulmonary artery, mim-
icked in our model by crossclamping of the pulmonary
artery, and bronchial collaterals do not have enough flow to
provide adequate lung perfusion. This phenomenon triggers
the production of hypoxia-inducible factor 1,13,26 which in
turns activates production of VEGF and expression of
VEGF receptors within the ischemic territory.27 Endothelial
cell ischemia-reperfusion leads to membrane lesions and
induces a dysfunction in signal transduction leading to nitric
oxide production. Attempts at producing pulmonary arterial
ring vasodilatation with increasing doses of VEGF were
unsuccessful in this model either before or after CPB.
Therefore no pharmacologic in vitro data were available to
demonstrate the interaction between VEGF and nitric oxide.
Tofukuji and colleagues28 showed that during myocardial
ischemia VEGF messenger RNA is upwardly regulated, as
is flk-1 messenger RNA. They also demonstrated that, de-
spite ischemia and reperfusion, relaxation of preconstricted
coronary arterioles to VEGF was statistically significantly
augmented and remained unchanged after use of receptor-
mediated endothelium-dependent vasodilator adenosine
diphosphate, which contrasts with the results of Chang and
associates.23 The difference in results may be multifactorial.
First, microvessels contain less smooth muscle and might be
more sensitive to vasodilator agonists than 2-mm diameter
pulmonary arterial rings. Second, in their model Tofukuji
and colleagues28 showed this particular type of vascular
reactivity after use of cardioplegia, whereas in this study
lungs were not subjected to any type of pharmacologic
protection. Finally, coronary and pulmonary circulations
may display different responses to vasodilators after isch-
emia and reperfusion.
Other possible explanations for the lack of nitric oxide
production related to VEGF accumulation might be an
endothelial NOS dysfunction, which was ruled out by the
calcium ionophore data; a downward regulation of VEGF
receptors, but none of our data can confirm or disconfirm
this hypothesis; or a questionable relationship between
VEGF and nitric oxide in the pulmonary vasculature, which
might be answered by use of a VEGF blocker; however, this
type of molecule is under experimentation in other medical
fields and was not available for our work. Finally, the fact
that acetylcholine is unable to relax pulmonary arterial rings
after CPB may simply be due to a downward regulation of
muscarinic receptors.
An additional probable effect of lung VEGF accumu-
lation was an increase in Kfc. Indeed, VEGF was previ-
ously known to be the vascular permeability factor, a
protein that promotes extravasation of proteins from tu-
mor-associated blood vessels. This observation is consis-
tent with the finding of increased lung water content after
CPB and explains some postoperative ventilatory prob-
lems. A statistically significant correlation between these
findings was found. VEGF has already been investigated
as a potential source of edema formation in the heart28
and brain29 after the ischemia-reperfusion phenomenon.
This correlation was even more relevant when muscular
VEGF was shown not to be statistically significantly
increased after bypass. This suggests that because skel-
etal muscles are not subjected to ischemia during CPB,
only ischemic territories express VEGF accumulation,
either through production or through higher receptor ex-
pression or affinity. A recent work by Abrahamov and
coworkers30 showed an independent correlation between
plasma VEGF and capillary leak syndrome in neonates
after CPB. This finding is not in contrast with those of
our work, because some soluble VEGF can be found in
the systemic circulation as a result of the excess in the
vicinity of the stressed territories.
In conclusion, this study demonstrates that total CPB
induces pulmonary hypertension with a pulmonary vascular
endothelial dysfunction through a multifactorial mechanism
that mainly includes ischemia-reperfusion phenomenon and
cytokine production. In addition to vasoconstrictors cyto-
kines endothelin 1 and thromboxane previously demon-
strated to intervene in this reaction,31 this work shows that
it is also probably related to membrane alterations or G
protein dysfunction, which in turns impairs signal transduc-
tion, leading to nitric oxide production with an accumula-
tion of upstream products. One of these products is VEGF,
which also increases vascular permeability and is probably
(in addition to other factors) responsible for post-CPB pul-
monary edema, a finding that is less pronounced in the
systemic nonischemic territories.
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